DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20173148

Pharmacovigilance in cancer chemotherapy in regional cancer center of Eastern India: prospective observational study

Anima Rout, Rajendra K. Panda, Vedvyas Mishra, Prasant Parida, Srikant Mohanty

Abstract


Background: Globally cancer is the leading cause of morbidity and mortality with annual death rate of 12%. According Indian Council of Medical Research, more than 1300 Indians die every day due to cancer. Chemotherapy is one of the multimodal approaches for treatment of cancer and regimens are much complex and cancer patients are more susceptible to adverse drug reaction with little tolerance due to diminished immunity. The present study was done to evaluate the prevalence of various adverse drug reactions with different cancer chemotherapy regimens, their nature and severity as well as their causality assessment as per WHO scale.

Methods: This prospective observational study was conducted from July 2015 to June 2016. Patients receiving cancer chemotherapy from regional cancer centre, Cuttack were observed during the study period for the adverse drug reactions. Those ADRs were analysed for causality assessment, severity and preventability.

Results: It was observed that after the initiation of chemotherapy, ADRs were observed in 92 (88.46%) patients. Among these 329 observed ADRs, during the study period, female predominance was observed in the age group 51-60yrs. Most common ADRs observed were nausea and vomiting 57 (17.37%), alopecia 46 (13.98%) and neutropenia 38 (11.55%). ADRs were most commonly seen with the haematological systems (37.68%) followed by gastrointestinal system amounting 25.22% of the total ADRs. Platinum Compound (58.35%), followed by antibiotics, antimetabolites, were the most common group of drugs causing different adverse drug reactions. On causality assessment, as per WHO-UMC criteria 68.38% were probable and 31.62% ADRs were possible. Severity assessment showed majority of the ADRs were moderate 228 (69.31%) followed by mild 67 (20.36%) and severe 34 (10.33%). It was observed that majority 212 (64.45%) of the ADRs were not preventable, 72 (21.88%) were definitely preventable and 45 (13.67%) were probably preventable.

Conclusions: Cancer chemotherapy has definitely improved the quality of life, but associated ADRs need early diagnosis, prompt management and routine reporting. Thus, pharmacovigilance will definitely reduce morbidity and mortality, so also the financial burden for the patients and society.


Keywords


Adverse drug reaction, Anticancerous drugs, Chemotherapy induced, Pharmacovigilance

Full Text:

PDF

References


Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer, Oral Oncol., 45(4), 309-16 (2009),Available from: http://www.oraloncology.com /article/ S1368-8375(08) 001838/fulltext, 2009

Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117-28.

www.ncrpindia.org

Chabner BA, Amrein PC, Druker BJ. Antineoplastic agents.In: Bruntan LL, Lazo JS, Parker KL, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 11th ed USA: McGraw-Hill Companies, Inc.; 2006. p. 1315.

Edward IR. Pharmacological basis of adverse drug reactions. In: Speight TM, Holford NHG, editors. Avery’s Drug Treatment. Chapter 9. Auckland: Adis International limited; 1997: 1852.

Hurwitz N, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. Br Med J. 1969;1(5643):531-6.5

Pirmohamed M, James S, Meakin S, Green C, Scott AK,Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 2004;329:15-9.

Gandhi, t.k.; Bartel, s.b.; Shulman, l.n; Verrier, d.; Burdick, e.; Cleary, a.; Rothschidl, j.m.; Leape, l.l.; Bates, d.w. Medication safety in ambulatory chemotherapy setting. Cancer, v.104, n.11, p.2477-2483, 2005.

Lau, P.M; Stewart, K.; Dooley, M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support. Care Cancer, v.12, n.9, p.626-633, 2004.

Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, et al.The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 2012;30:3012-9

Kshirsagar NA, Karande SC, Potkar CN. Adverse drug reaction monitoring in India. J Assoc Physicians India 1993;41:374-6.

WHO-UMC standardized case causality assessment,(2011) Available from: http://who umc.org/Graphics/24734.pdf, (2011)

Hartwig SC, Siegel J and Schneider PJ., Preventability and severity assessment in reporting adverse drug

reactions, Am J Hosp Pharm., 49, 2229-32 (1992)

Schumock GT and Thornton JP., Focusing on the Preventability of Adverse Drug Reactions, Hosp. Pharm., 27(6), 538 (1992)

Saini V, Medhi B, Sewal R, Ahmad Y. Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a tertiary care hospital. Indian Journal of Pharmaceutical Sciences. 2015;77(6):687.

Prasad A, Datta PP, Bhattacharya J, Pattanayak C, Chauhan AS, et al. (2013) Pattern of Adverse Drug Reactions Due to Cancer chemotherapy in a Tertiary Care Teaching Hospital in Eastern India. J Pharmacovigilance 1: 107. doi:10.4172/2329-6887.1000107

Mallik S, Palaian S, Ojha P, Mishra P. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Nepal. Pak J Pharm Sci 2007;20:214-8.

Goyal YN, Solanki KC, Mistry RA, Joshi ND, Singh AP, Gajera MVPattern of adverse drug reactions due to cancer chemotherapy in tertiary care teaching hospital in Gujarat. Int J Sci Res 2014;3:333-5

Swathi B, Bhavika D, Begum N. Adverse drug reaction profi les of commonly used platinum compounds in cancer chemotherapy. Int J Basic Clin Pharmacol 2015;4:284-9.

Sharma A, Kumari KM, Manohar HD, Bairy KL,Thomas J. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care hospital in South India. Perspect Clin Res 2015;6:109-15.

Poddar S, Sultana R, Sultana R, Akbor MM, Azad MA, Hasnat A.Pattern of adverse drug reactions due to cancer chemotherapy in tertiary care teaching hospital in Bangladesh. Dhaka Univ J PharmSci 2009;8:11‑6.

Surendiran A, Balamurugan N, Gunaseelan K, Akhtar S, Reddy KS, Adithan C. Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. Indian J Pharmacol. 2010;42(1):40-3

Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol. 1998;46(5):505-11.

Bellare PS, Ashwin K, Pu SP, Vinaykumar S, Kb R. A Retrospective Evaluation of Adverse Drug Reactions Due to Cancer Chemotherapy in a Tertiary Care Hospital in South India. Journal of Young Pharmacists. 2016Jan;8(3):251–4.

Soldin OP, Chung SH, Mattison DR. Sex differences in drug disposition. J Biomed Biotechnol 2011;2011:187103.

Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004;44:499‑523.

Hanlon JT, Ruby CM, Artz M. Geriatrics. In: DiPiro JT, Talbert RL,Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy A Pathophysiologic Approach. 5th ed. New York: McGraw Hill Inc.;2002. p. 79‑89.

Kaur K, Sood M, Bhagat S, Singh T, Jain M, Arora D, et al. Spontaneous adverse drug reaction monitoring in oncology: Our experience. Indian Journal of Cancer. 2015;52(3):467.

Chopra D, Rehan HS, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: A prospective observational survey. Indian J Med Paediatric Oncol 2016;37:42-6.

G. Lakshmi Durga, T.V. Sivaramakrishna, A. Ramya, S. Mounika, G. Anusha Medication Utilization in Incident Adverse Drug Reactions of Cancer Chemotherapy in a Tertiary Care Hospital Jour of Pharm and Biolo Sci Volume 10, Issue 2 Ver. IV (Mar -Apr. 2015), PP 05-09

Kirthi C, Afzal A, Reddy M, Ali SA, Yerramilli A, Sharma S. A studyon the adverse effects of anticancer drugs in an oncology center of a tertiary care hospital. Int J Pharm Pharm Sci 2014;6:580-3.

A De. Monitoring of suspected adverse drug reactions in oncology unit of an urban multispeciality teaching hospital.Int J Res Pharm Biomed Sci (online) 2010;1:1-32.